Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.34 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5596416 | 0.86 | NOTUM (0.37) | HTR6DRD2NOTUMTAAR1 | |
| SCHEMBL5596733 | 0.86 | NOTUM (0.35) | DRD2NOTUMTAAR1 | |
| SCHEMBL5597035 | 0.81 | NOTUM (0.34) | HTR6DRD2NOTUMCDK9PIM1 | |
| SCHEMBL5596755 | 0.81 | NOTUM (0.32) | NOTUM | |
| SCHEMBL5597030 | 0.79 | PRKCZ (0.34) | ROCK2ROCK1HTR6DRD2PARP1 | |
| SCHEMBL5596844 | 0.79 | NOTUM (0.36) | HTR6DRD2PARP1NOTUMCDK9 | |
| SCHEMBL5410387 | 0.79 | HTR2C (0.47) | ROCK2ROCK1HTR6DRD2 | |
| SCHEMBL5596700 | 0.79 | GRIN2B (0.41) | ROCK2ROCK1CXCR4 | |
| SCHEMBL5596996 | 0.78 | HTR6 (0.36) | HTR6DRD2PARP1NOTUMPRKD3 | |
| SCHEMBL5596620 | 0.78 | DRD2 (0.39) | HTR6DRD2PARP1NOTUMPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | ROCK2 255/4885ROCK1 29/4885HTR6 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.